	Beneficio Bruto En Ventas		Fecha
AbbVie	USD 10.47B	605M	2025-09
Amgen	USD 6.48B	307M	2025-09
Anika Therapeutics	USD 14.68M	9.46M	2025-03
Arrowhead Research	USD 256.47M	228.7M	2025-09
AstraZeneca	USD 12.39B	5M	2025-12
BioCryst Pharmaceuticals	USD -88.88M	202.74M	2024-12
Biogen	USD 1.65B	34.6M	2025-12
Bristol-Myers Squibb	USD 8.79B	110M	2025-09
Enanta Pharmaceuticals	-22.29M	23.75M	2024-12
Gilead Sciences	USD 6.2B	620M	2025-09
GlaxoSmithKline	GBP 6.18B	106M	2025-12
Halozyme Therapeutics	USD 281.77M	2.41M	2025-09
Heron Therapeutics	USD 23.35M	1.6M	2024-09
Immunic	0	0	2025-03
Incyte	USD 1.39B	118.68M	2025-12
Insmed	USD 111.44M	33.36M	2025-09
Ionis Pharmaceuticals	USD 155M	293M	2025-09
J&J	USD 16.6B	118M	2025-12
Karyopharm Therapeutics	USD -30.78M	1.29M	2024-12
Ligand Pharmaceuticals	USD 155.28M	82.42M	2025-09
Merck	USD 13.42B	431M	2025-09
Neurocrine Biosciences	USD 780.9M	104.7M	2025-09
Novartis	USD 10.82B	695M	2025-09
Novavax	USD 23.89M	239.21M	2024-09
Pfizer	USD 3.54B	7.61B	2025-09
PTC Therapeutics	USD 187.69M	24.3M	2025-09
Roche Holding	CHF 22.09B	10.04B	2025-12
Sarepta Therapeutics	USD 247.9M	209.96M	2025-09
Vertex Pharmaceuticals	USD 2.66B	104.4M	2025-09

Enanta Pharmaceuticals Beneficio Bruto En Ventas - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Feb 2026.